Next-Generation Nutraceuticals: Food and pharma convergence in disease prevention and personalized nutrition

Table of Contents

Executive Summary

• Food and pharmaceutical disease prevention
• Functional food and drinks
• Technologies for nutrigenomics
• The regulatory landscape
• Strategies of leading ingredient, food, drinks and pharma companies
• Future challenges and opportunities

Chapter 1 Food and pharmaceutical disease

• prevention
• Summary
• Introduction
• The changing approach to the health burden
• New technologies
• Key convergent markets
• Obesity
  • Epidemiology
  • Sales
• Cardiovascular disease
  • Epidemiology
  • Sales
• Diabetes
  • Epidemiology
  • Sales
• Bone health
  • Epidemiology
  • Sales
• Conclusions

Chapter 2 Functional food and drinks

• Summary
• Introduction
• Functional food and drinks
• Functional ingredients
• Scientific evidence to support the health benefits of functional ingredients
  • Proving efficacy: pharma vs. food
• Growth areas and product trends in the functional foods market
  • Heart health
  • Digestive health - Probiotics
  • Innovative ingredients aligning with pharma
• Personalized nutrition
• Conclusions

Chapter 3 Technologies for nutrigenomics

• Summary
• Introduction
• Biomic technologies in the pharma industry
• Pharma technologies in the food industry
• Genomics
  • Genomics in personalized nutrition
  • Case study: Sciona Inc
• Transcriptomics
  • Transcriptomics in the food industry
  • Case study: WellGen Inc.
• Proteomics
• Metabolomics
  • Case study: the INTERMAP study
  • Challenges to metabolomics in nutrition research
  • Growth and interest in metabolomics
• Systems Biology
• Nanotechnology delivering new ingredients
• Conclusions

Chapter 4 The regulatory landscape

• Summary
• Introduction
• Regulation of health claims for functional foods
• Japan
• United States
  • Health claims
  • Structure/function claims
  • Criticism of the FDA' s approach
• Europe
• Opportunities and threats of functional food regulation
• The future of functional food regulation
• Regulation of personalized dietary advice
• Conclusions

Chapter 5 Strategies of leading ingredient,

• food, drinks and pharma
• companies
• Summary
• Introduction
• Ingredient manufacturers
• DSM
• BASF
• Chr. Hansen
  • Products
  • Research
• Opportunities for the ingredients industry
• Food and drinks manufacturers
• Nestlé
  • Nestlé' s products
  • Research
  • The future for Nestlé
• Unilever
  • Unilever' s products
  • Research
  • The future for Unilever
• Ajinomoto
  • Research and the future for Ajinomoto
• Danone
  • The future for Danone
• Coca-Cola
• Other food and drinks manufacturers
• Pharma companies
• Future trends for the food and pharma industries
• Agribusiness
• Alliances
• Food-pharma alliances
• Alliances with new technology companies
• Alliances for nutrigenomic research
• Conclusions

Chapter 6 Future challenges and

• opportunities
• Summary
• Introduction
• Opportunities and market drivers
• Consumer demand
• Incentives
• Opportunities in developing markets
• New product development opportunities
• Marketing
• Challenges
• Scientific challenges
  • Furthering basic and applied research
  • Clinical testing of nutraceuticals
  • Defining health
• Ethical, legal and societal concerns
  • Ethical concerns
  • Societal concerns
  • Privacy and human rights
  • Research practices in nutrigenomics
• The regulatory framework
• Conclusions

Chapter 7 Appendix

• Bibliography
• Index
• Footnotes

List of Figures

• Figure 1.1: Drivers of change in the food and pharma industries
• Figure 1.2: Examples of food and pharma approaches to heart disease
• Figure 1.3: A functional food pyramid
• Figure 1.4: The role of food and pharmaceuticals in the healthcare continuum
• Figure 1.5: Examples of obesity drugs in development
• Figure 1.6: Global deaths from cardiovascular disease
• Figure 1.7: Drugs in clinical development for CV disorders
• Figure 2.8: Top US consumer health concerns, 2005
• Figure 2.9: Nutrigen IQ3 Yogurt Drink
• Figure 2.10: Right Direction Cookies
• Figure 2.11: DanaCol with Omega-3 & Plant Sterols Dairy Drink
• Figure 2.12: Calpis Aqua Nyusankin
• Figure 2.13: Calpis Interbalance L-92 Lactic Acid Bacteria Drink
• Figure 3.14: The ' omics technologies: definitions
• Figure 3.15: The ' omics technologies
• Figure 3.16: The Cellf™ Assessment Kit from Sciona
• Figure 3.17: Pro-inflammatory metabolic pathways
• Figure 3.18: Technologies used in proteomics
• Figure 3.19: 1H NMR spectrum of urine showing functional windows
• Figure 3.20: Large scale metabolomic screening of human populations: identifying outliers
• Figure 4.21: Standardized qualifying language for qualified health claims
• Figure 4.22: Examples of structure/function claims allowed on food labeling
• Figure 5.23: Recent products launched that contain TEAVIGO™
• Figure 5.24: Development of new probiotic cultures at Chr. Hansen
• Figure 5.25: Nestlé' s products by functional category, 2004-2006
• Figure 5.26: Nestlé' s functional brands (2005)
• Figure 5.27: Nestle NesVita Pro-Heart Probiotic Drink
• Figure 5.28: Unilever' s products by functional category, 2004-2006
• Figure 5.29: Flora Pro-Active Blood Pressure Mini Drink
• Figure 5.30: Ajinomoto products by functional category, 2004-2006
• Figure 5.31: Calpis Ameal S Maiasa Yasai (vegetable breakfast drink)
• Figure 5.32: Danone' s products by functional category, 2004-2006
• Figure 5.33: Danone Petit Danone Cheese Dessert
• Figure 5.34: Coca-Cola' s products by functional category, 2004-2006
• Figure 5.35: Enviga
• Figure 5.36: Novartis' Benefiber Clear Choice! Powder and Isocal Jelly Arg Jelly Dessert
• Figure 6.37: Awareness and favorability towards personalized nutrition

List of Tables

• Table 1.1: Number and percentage of overweight and obese adults by country, 2005-2010 (% adult population)
• Table 1.2: Size of the diet food and drinks market and the obesity pharmaceutical market, (US$,m), 2005-2010
• Table 1.3: Estimated prevalence of major cardiovascular diseases in the seven major markets, 2004
• Table 1.4: Size of the food and drinks and pharmaceutical markets for heart health, (US$,m), 2005-2010
• Table 1.5: Prevalence of type-2 diabetes in the 7 major markets, 2005-11
• Table 1.6: Size of the pharmaceutical market for diabetes, (US$,m), 2005-2010
• Table 1.7: Prevalence of Rheumatoid Arthritis based on population > 60 in the seven major markets (000s), 2005-2010
• Table 1.8: Prevalence of osteoporosis in men and women over 50 across the seven major markets, 2005
• Table 1.9: Size of the food and drinks and pharmaceutical markets for bone health, (US$m), 2005-2010
• Table 2.10: Functional ingredients
• Table 2.11: Functional food ingredients (cont.)
• Table 2.12: Examples of functional food ingredients and the scientific basis for health benefit claims
• Table 2.13: Functional food and drink sales by value ($m), 2005-2008
• Table 3.14: Companies offering nutrigenetic testing and dietary advice, 2006
• Table 3.15: Genetic variations screened by the Cellf™ Assessment Kit from Sciona, 2006
• Table 3.16: How nutrients alter gene expression
• Table 3.17: Examples of transcriptomics in nutritional biology and nutrigenomics
• Table 3.18: Companies and research centres utilizing gene expression analysis for nutrigenomic applications
• Table 4.19: FOSHU functions and functional food components
• Table 4.20: Generic health claims currently approved by the FDA
• Table 4.21: Regulatory opportunities and threats in the functional foods industry
• Table 5.22: Ajinomoto products containing AmealPeptide™ launched in Japan
• Table 5.23: Recent functional food and drinks launches
• Table 5.24: Some functional food and drink products launched by pharma companies
• Table 5.25: Consortia involved in the International Nutrigenomics Network
• Table 5.26: Examples of other collaborative nutrigenomic research projects
• Table 6.27: Biomarkers for well-being and disease risk reduction